Viking Therapeutics Set to Announce Second Quarter 2025 Financial Results on July 23rd
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine diseases, has announced it will report its financial results for the second quarter of 2025 after market close on Tuesday, July 23, 2025.
The company plans to provide an update on its business and financial performance, including a review of key clinical development milestones and strategic initiatives. Investors and interested parties will be able to access the financial results release on the company’s investor relations website.
In addition to the release of its quarterly results, Viking Therapeutics will also host a conference call and webcast later that day, at 4:30 PM Eastern Time (1:30 PM Pacific Time). The conference call will feature management’s discussion of the second quarter results, along with an overview of the company’s pipeline and future outlook. A replay of the webcast will be available on the Viking Therapeutics investor relations website following the call.
This announcement is a routine update for publicly traded companies, providing stakeholders with timely information regarding the company’s financial health and operational progress. Investors will be keen to hear about any advancements in Viking Therapeutics’ clinical trials, particularly for its promising drug candidates targeting conditions such as non-alcoholic steatohepatitis (NASH) and obesity.
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025’ at 2025-07-16 20:05. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.